
Company valuation, historical trends, and peer comparisons.
According to Incyte Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 21.09B. This represents a change of 17.16% compared to the average of 18.00B of the last 4 quarters.
The mean historical Enterprise Value of Incyte Corporation over the last ten years is 15.31B. The current 21.09B Enterprise Value has changed 37.77% with respect to the historical average. Over the past ten years (40 quarters), INCY's Enterprise Value was at its highest in in the March 2017 quarter at 25.78B. The Enterprise Value was at its lowest in in the March 2024 quarter at 9.41B.
Average
15.31B
Median
15.59B
Minimum
10.87B
Maximum
18.84B
Discovering the peaks and valleys of Incyte Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 37.29%
Maximum Annual Enterprise Value = 18.84B
Minimum Annual Increase = -33.10%
Minimum Annual Enterprise Value = 10.87B
| Year | Enterprise Value | Change |
|---|---|---|
| 2025 | 16.25B | 28.36% |
| 2024 | 12.66B | 16.51% |
| 2023 | 10.87B | -27.17% |
| 2022 | 14.92B | 5.33% |
| 2021 | 14.17B | -19.06% |
| 2020 | 17.50B | 2.99% |
| 2019 | 16.99B | 37.29% |
| 2018 | 12.38B | -33.10% |
| 2017 | 18.50B | -1.79% |
| 2016 | 18.84B | -3.78% |
The current Enterprise Value of Incyte Corporation (INCY) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
13.26B
5-year avg
13.77B
10-year avg
15.31B
Incyte Corporation’s Enterprise Value is less than Genmab A/S (37.87B), greater than Exelixis, Inc. (17.92B), greater than Cullinan Therapeutics, Inc. (841.00M), less than Regeneron Pharmaceuticals, Inc. (98.60B), greater than Nurix Therapeutics, Inc. (2.16B), greater than Ligand Pharmaceuticals Incorporated (7.27B), greater than Verastem, Inc. (824.98M), greater than Legend Biotech Corporation (3.56B), greater than SELLAS Life Sciences Group, Inc. (1.61B), greater than ArriVent BioPharma, Inc. (525.62M),
| Company | Enterprise Value | Market cap |
|---|---|---|
| 37.87B | $34.23B | |
| 17.92B | $18.06B | |
| 841.00M | $917.57M | |
| 98.60B | $99.55B | |
| 2.16B | $2.82B | |
| 7.27B | $6.19B | |
| 824.98M | $877.01M | |
| 3.56B | $3.96B | |
| 1.61B | $1.75B | |
| 525.62M | $679.95M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Incyte Corporation using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Incyte Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is Incyte Corporation's Enterprise Value?
What is the highest Enterprise Value for Incyte Corporation (INCY)?
What is the 3-year average Enterprise Value for Incyte Corporation (INCY)?
What is the 5-year average Enterprise Value for Incyte Corporation (INCY)?
How does the current Enterprise Value for Incyte Corporation (INCY) compare to its historical average?